Shares of Spire Healthcare Group plc (LON:SPI - Get Free Report) passed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of GBX 219.21 ($2.95) and traded as high as GBX 222 ($2.99). Spire Healthcare Group shares last traded at GBX 222 ($2.99), with a volume of 277,651 shares.
Analysts Set New Price Targets
Several brokerages have recently commented on SPI. Berenberg Bank restated a "buy" rating and issued a GBX 280 price objective on shares of Spire Healthcare Group in a report on Thursday, July 31st. JPMorgan Chase & Co. decreased their price objective on shares of Spire Healthcare Group from GBX 309 to GBX 303 and set an "overweight" rating on the stock in a report on Tuesday, August 5th. Three analysts have rated the stock with a Buy rating, According to data from MarketBeat, Spire Healthcare Group currently has an average rating of "Buy" and an average target price of GBX 294.33.
Read Our Latest Analysis on SPI
Spire Healthcare Group Stock Up 0.3%
The business has a 50-day moving average price of GBX 219.21 and a two-hundred day moving average price of GBX 205.29. The company has a quick ratio of 0.74, a current ratio of 0.70 and a debt-to-equity ratio of 62.25. The firm has a market cap of £894.04 million, a PE ratio of 31.69, a price-to-earnings-growth ratio of 1.06 and a beta of 0.96.
Spire Healthcare Group (LON:SPI - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The company reported GBX 4.10 earnings per share for the quarter. Spire Healthcare Group had a return on equity of 3.82% and a net margin of 1.96%. On average, equities research analysts expect that Spire Healthcare Group plc will post 15.6634747 EPS for the current year.
About Spire Healthcare Group
(
Get Free Report)
Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics. It offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening and surgery, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Spire Healthcare Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Spire Healthcare Group wasn't on the list.
While Spire Healthcare Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access